Emerging immunotherapy modalities in AML and exciting data from ASH 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked: What are the emerging immunotherapy modalities in AML and what data from ASH 2019 is exciting in the AML immunotherapy field? Naval Daver talks about emerging immunotherapies in the field of AML. He describes the expansion of knowledge in this field and how that has helped improve patient outcomes, such as the identification of PD-1 checkpoint as a therapeutic target and the subsequent development of therapies. He discusses studies that examine the efficacy of combination therapies, and he explains the importance of using the patient's immune profile to guide the treatment pathway.